Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation
Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation
复制标题
[131I]美妥昔单抗治疗经皮射频消融术后肝细胞癌的随机试验。
DOI：
10.1093/jnci/dju239
复制
发表时间：
2014-09-01
影响因子：
10.3
通讯作者：
Chen, Zhi-Nan
中科院分区：
文献类型：
--
作者：
Bian, Huijie;Zheng, Jia-Sheng;Chen, Zhi-Nan
为了评估放射免疫偶联物[（131）I]美妥昔单抗联合射频消融（RFA）治疗肝细胞癌（HCC）与单纯RFA相比的疗效，对127例巴塞罗那临床肝癌分期系统（BCLC）0-B期患者进行了一项单中心随机对照试验。患者接受RFA后[（131）I]美妥昔单抗（n = 62）或单独RFA（n = 65）。主要结局是总体肿瘤复发。统计检验是双侧的。联合组的1年和2年复发率分别为31.8%和58.5%，而RFA组分别为56.3%和70.9%。联合治疗组中至总体肿瘤复发的中位时间为17个月，RFA组为10个月（P = 0.03）。RFA-[（131）I]美妥昔单抗治疗在美妥昔单抗靶点（即CD 147）阳性亚群中显示出比RFA更大的抗复发获益（P = .007）。[（131）I]美妥昔单抗可预防RFA后肿瘤复发。
To assess the efficacy of combining radioimmunoconjugate [(131)I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0-B stage. Patients received either RFA followed by [(131)I] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one- and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[(131)I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)-positive subpopulation (P = .007). [(131)I] metuximab may yield prevention of tumor recurrence after RFA.